What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors

On May 15, 2026, Saturn V Capital Management disclosed a full exit from Ocular Therapeutix (NASDAQ:OCUL), selling 1,504,880 shares in a trade estimated at $14.34 million based on quarterly average pricing.According to an SEC filing dated May 15, 2026, Saturn V Capital Management sold its entire 1,504,880-share holding in Ocular Therapeutix. The estimated transaction value was $14.34 million, calculated using the average closing price for the first quarter of 2026. The fund's reported position in the stock fell to zero, with a quarter-end valuation shift of $18.27 million reflecting both trading and market price movement.Ocular Therapeutix is a biopharmaceutical company with a focus on innovative drug delivery solutions for ophthalmic diseases. The company combines proprietary hydrogel technology with established and novel therapeutics, aiming to address unmet medical needs in eye care. Strategic collaborations and a diversified pipeline position Ocular Therapeutix to compete in the growing market for advanced ophthalmic therapies.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool